Journals / Anadolu Psikiyatri Dergisi / 2014 / Cilt: 15 - Sayı: 4

The use of cytochrome P450 phenotyping in psychiatry

Psikiyatride sitokrom P450 fenotiplemesinin kullanımı

Pages
358–364
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Recently some phenotyping methods are becoming widely used especially for the in vivo evaluation of multiple cytochrome enzymes by using probe cocktails.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Individualization of pharmacotherapy is essential in order to optimize efficacy and minimize toxicity, especially for compounds with narrow therapeutic index.
📊
Key Findings & Data:Cytochrome P450 phenotyping has been a valuable research tool and a way of assessing the genetic basis of metabolic capacity.
💡
Conclusion & Impact:Recently some phenotyping methods are becoming widely used especially for the in vivo evaluation of multiple cytochrome enzymes by using probe cocktails.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Individualization of pharmacotherapy is essential in order to optimize efficacy and minimize toxicity, especially for compounds with narrow therapeutic index. Cytochrome P450 phenotyping has been a valuable research tool and a way of assessing the genetic basis of metabolic capacity. Technique depends on estimating metabolic capacity based on conclusions drawn from another probe drug. Phenotyping allows estimation of the total influence of drug interactions, genetic polymorphisms, hepatic diseases and other factors altering pharmacokinetics. This requires the use of selective substrates for specific cytochrome enzymes. Recently some phenotyping methods are becoming widely used especially for the in vivo evaluation of multiple cytochrome enzymes by using probe cocktails.

Özet

Özellikle tedavisel aralığı dar olan ilaçlar için tedavi etkinliğini sağlayabilmek, yan etkileri en aza indirebilmek için farmakolojik tedavinin kişiye özel uygulanması gereklidir. Sitokrom P450 enzimlerinin fenotiplemesi hem değerli bir araştırma yöntemi, hem de metabolik kapasitesinin genetik temelinin değerlendirilmesi için bir araçtır. Teknik, bir prob ilaç (ölçüm maddesi) kullanarak metabolik kapasitenin tahmin edilmesine dayanır. Fenotipleme ilaç etkileşimleri, genetik polimorfizmler, hepatik hastalıklar ve ilacın farmakokinetiğini etkileyebilecek diğer etkenlerin toplam etkisini gösterir. Bunun için fenotiplemede her bir sitokrom enzim sistemine özgü substratların kullanımı gereklidir. Son dönemde birden fazla sitokrom enzim sisteminin in vivo değerlendirmesine olanak tanıyan ölçüm maddeleri kokteylleri ile fenotipleme kullanılmaya başlanmıştır.

🔖

Cite This Article

SAYAR, F. G. H., ERYILMAZ, G., ÖZTEN, E., GÖĞCEGÖZ, I. G., CEYLAN, M. E. (2014). The use of cytochrome P450 phenotyping in psychiatry. Anadolu Psikiyatri Dergisi, Cilt: 15 - Sayı: 4, 358–364. https://ajindex.com/articles/355822

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Gervasini G, Benítez J, Carrillo JA. Pharmaco genetic testing and therapeutic drug monitoring are complementary tools for optimal individuali- zation of drug therapy. Eur J Clin Pharmacol 2010; 66:755-774.
  2. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribu- tion of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9:442-473. Çetin M. Psikiyatrik uygulamada ilaç etkileşimleri. Klinik Psikofarmakoloji Bülteni 1999; 9:78-92.
  3. Arıcıoğlu F, Çetin M. Psikiyatride bireye özgü tedavi: Belki biraz eski veya biraz yeni, ama gele- ceğin tedavisi. BCP 2010; 20:269-273. De LeonJ. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer pheno- types in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J Clin Psychopharmacol 2007; 27:241-245.
  4. Wehmeier PM, Gebhardt S, Schmidtke J, Rem- schmidt H, Hebebrand J, Theisen FM. Clozapine: weight gainin apair of monozygotic twins concor- dant for schizophrenia and mild mental retarda- tion. Psychiatry Res 2005; 133:273-276.
  5. Coutts RT, Urichuk LJ. Polymorphic cytochromes P450 and drugs used in psychiatry. Cell Mol Neurobiol 1999; 19:325-354. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient phar- macotherapy. J Intern Med 2001; 250:186-200.
  6. Demet MM, Deniz F, Şimşek E, Taşkın EO, Deveci A. Psikotrop ilaç yazılma sıklığı ve ilaç etkileşimleri: sitokrom P450 sistemi. BCP 2003; 13:43-49. Daly AK. Development of analytical technology in pharmacogenetic research. Naunyn Schmiede- bergs Arch Pharmacol 2004; 369:133-140. Kirchhener J. The CYP2D6 activity score trans- lating gynotype information into aqualitative mea- sure of phenotype. Clin Pharmacol Ther 2008; 83:234-242. Kirchheiner J. CYP2D6 phenotype prediction from genotype: Which system is the best? ClinPharmacol Ther 2008; 83:225-227.
  7. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry 2011; 44:195-235.
  8. Streetman DS, Bertino JS, Nafziger AN. Pheno- typing of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10:187-216.
  9. Schmitz G, Aslanidis C, Lackner KJ. Pharma- cogenomics: implications for laboratory medicine. Clinica Chemica Acta 2001; 308:43-53.
  10. Zaigler M, Tantcheva